TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

about

Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

P2860

Q38741543-928D3FEF-1617-4674-909E-CA3A8FD70AA1 Q47102779-DDAEC069-3D82-464D-B866-9DA2E7A9D93B

P2860

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

Item

http://www.wikidata.org/entity/Q41133791

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

TKI sensitivity patterns of no ...... ts with resistant ALK+ tumors.

@en

type

Item

label

TKI sensitivity patterns of no ...... ts with resistant ALK+ tumors.

@en

prefLabel

TKI sensitivity patterns of no ...... ts with resistant ALK+ tumors.

@en

P1476

TKI sensitivity patterns of no ...... nts with resistant ALK+ tumors

@en

P2093

Amit Dipak Amin

http://www.w3.org/2001/XMLSchema#string

Edgar O Tapia

http://www.w3.org/2001/XMLSchema#string

Lingxiao Li

http://www.w3.org/2001/XMLSchema#string

Matthew J Groysman

http://www.w3.org/2001/XMLSchema#string

Mengdie Wang

http://www.w3.org/2001/XMLSchema#string

Praechompoo Pongtornpipat

http://www.w3.org/2001/XMLSchema#string

Soumya S Rajan

http://www.w3.org/2001/XMLSchema#string

Vijay Gokhale

http://www.w3.org/2001/XMLSchema#string

P2860

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

An overview of the c-MET signaling pathway

Identification of ALK as a major familial neuroblastoma predisposition gene

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

P304

23715-23729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8173

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan H Schatz

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27009859

http://www.w3.org/2001/XMLSchema#string

P932

5029658

http://www.w3.org/2001/XMLSchema#string

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

about

P2860

P2860

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932